PM
AKRO

Prosight Management’s Akero Therapeutics AKRO Stock Holding History

Prosight Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-39,072
Closed -$1.86M – 40
2025
Q3 		$1.86M Buy
+39,072
New +$1.89M 0.43% 33

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prosight Management's AKRO Position: Q4 2025 in Review

Prosight Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 39,072 shares — an estimated $1.86M sold.

Prosight Management first reported a position in AKRO in Q3 2025 and held it in 1 quarter. The position peaked at $1.86M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Prosight Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Prosight Management sold 39,072 Akero Therapeutics shares in Q4 2025, an estimated $1.86M.
  • Prosight Management first reported a position in Akero Therapeutics in Q3 2025 and held it in 1 quarter.
  • Prosight Management's Akero Therapeutics position peaked at $1.86M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Prosight Management's 13F filing for Q4 2025, filed 13 Feb 2026.